GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » Debt-to-Revenue

Biotage AB (Biotage AB) Debt-to-Revenue : 0.21 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biotage AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Biotage AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.2 Mil. Biotage AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $35.3 Mil. Biotage AB's annualized Revenue for the quarter that ended in Mar. 2024 was $184.4 Mil. Biotage AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.21.


Biotage AB Debt-to-Revenue Historical Data

The historical data trend for Biotage AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Debt-to-Revenue Chart

Biotage AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.15 0.17 0.14 0.14

Biotage AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.23 0.23 0.10 0.21

Competitive Comparison of Biotage AB's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Biotage AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biotage AB's Debt-to-Revenue falls into.



Biotage AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Biotage AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.217 + 22.032) / 181.524
=0.14

Biotage AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.17 + 35.25) / 184.416
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Biotage AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biotage AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB (Biotage AB) Business Description

Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (Biotage AB) Headlines

From GuruFocus

Biotage AB (publ) Interim Report January - March 2020

By PRNewswire PRNewswire 04-28-2020

Issue and re-purchase of class C shares for incentive program

By PRNewswire PRNewswire 08-18-2020

Biotage - change in number of shares and votes

By PRNewswire PRNewswire 08-31-2020

Biotage appoints Nomination Committee

By PRNewswire PRNewswire 09-24-2020

Biotage AB (publ) appoints new CFO

By PRNewswire PRNewswire 07-01-2021

Biotage AB (publ) Interim report January-September 2020

By PRNewswire PRNewswire 11-05-2020

Berenberg Bank is now covering Biotage AB (publ) (BIOT)

By PRNewswire PRNewswire 06-29-2021

Biotage AB (publ) Year-end report January - December 2021

By PRNewswire PRNewswire 02-11-2022

Issue and re-purchase of class C shares for incentive program

By PRNewswire PRNewswire 11-30-2021